Table 2.
Clinical characteristics of PCOS cases and controls
| IR-PCOS (n = 94) | Non-IR-PCOS (N = 47) | Control (n = 123) | |
|---|---|---|---|
| Age (years) (range) | 27.8 ± 4.1 (20–39) | 27.4 ± 4.7 (20–38) | 27.9 ± 4.3 (20–41) |
| BMI (Kg/m2) | 23.8 ± 4.5a,b | 21.9 ± 2.9a | 21.7 ± 2.6b |
| LH (IU/L) | 13.3 ± 7.6a | 12.7 ± 8.1b | 4.4 ± 2.0a,b |
| FSH (IU/L) | 5.5 ± 1.8 | 5.6 ± 2.1 | 5.7 ± 1.8 |
| LH/FSH | 2.4 ± 0.5a | 2.3 ± 0.6b | 0.8 ± 0.4a,b |
| PRL (ng/mL) | 11.6 ± 8.5 | 12.1 ± 7.6 | 11.7 ± 4.6 |
| E2(pg/mL) | 53.9 ± 36.8 | 52.7 ± 37.9 | 46.9 ± 40.1 |
| T (pg/mL) | 57.1 ± 33.0a | 56.9 ± 34.1b | 44.0 ± 12.2a,b |
| AMH (ng/ml) | 13.3 ± 5.2a | 12.1 ± 5.6b | 3.7 ± 1.4a,b |
| HOMA-IR | 2.9 (2.7, 3.8)a,b | 1.9 (1.4, 2.6)b | 1.8 (1.2, 2.6)a |
Values are means ± SD, median (95 % confidence)
PCOS polycystic ovary syndrome, BMI body mass index, LH luteinizing hormone, FSH follicle stimulating hormone, PRL prolactin, E2 estradiol, T testosterone
a,bSimilar superscripts indicate a statistically significant difference (P < 0.01)